Thursday, April 19, 2012
As information about the genetic underpinnings of autism spectrum
disorder has proliferated, so too have questions about how subtle changes in a
seemingly diverse set of genes can lead to similar clinical pathology. This
month, an academic-industry consortium headed by King's College London and Roche launched with €29.6
million ($38.9 million) to develop research tools and diagnostics for the disorder
and to help select clinical endpoints for future trials.
Osherovich, L. SciBX 5(16);
Published online April 19, 2012
1. Sanders, S.J. et al. Nature; published online April 4, 2012;
2. O'Roak, B.J. et al. Nature; published online April 4, 2012;
3. Neale, B.M. et al. Nature; published online April 4, 2012;
AND INSTITUTIONS MENTIONED
Autism Speaks, New York, N.Y.
Centers for Disease Control and Prevention, Atlanta, Ga.
Foundation for the National Institutes of Health, Bethesda, Md.
Innovative Medicines Initiative, Brussels, Belgium
King's College London, London, U.K.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland